Anti-BRAF/anti-MEK targeted therapies for metastatic melanoma patients during the COVID-19 outbreak : experience from an Italian skin cancer unit
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
Future oncology (London, England) - 17(2021), 7 vom: 17. März, Seite 759-761 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Quaglino, Pietro [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Advanced metastatic melanoma |
|---|
| Anmerkungen: |
Date Completed 22.02.2021 Date Revised 22.02.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2217/fon-2020-0997 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM320945022 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM320945022 | ||
| 003 | DE-627 | ||
| 005 | 20231225174746.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/fon-2020-0997 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1069.xml |
| 035 | |a (DE-627)NLM320945022 | ||
| 035 | |a (NLM)33533662 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Quaglino, Pietro |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Anti-BRAF/anti-MEK targeted therapies for metastatic melanoma patients during the COVID-19 outbreak |b experience from an Italian skin cancer unit |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.02.2021 | ||
| 500 | |a Date Revised 22.02.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Editorial | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a advanced metastatic melanoma | |
| 650 | 4 | |a targeted therapies | |
| 650 | 7 | |a Proto-Oncogene Proteins B-raf |2 NLM | |
| 650 | 7 | |a EC 2.7.11.1 |2 NLM | |
| 650 | 7 | |a Mitogen-Activated Protein Kinase Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.12.2 |2 NLM | |
| 700 | 1 | |a Fava, Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Brizio, Matteo |e verfasserin |4 aut | |
| 700 | 1 | |a Marra, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Rubatto, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Merli, Martina |e verfasserin |4 aut | |
| 700 | 1 | |a Tonella, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Ribero, Simone |e verfasserin |4 aut | |
| 700 | 1 | |a Fierro, Maria Teresa |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Future oncology (London, England) |d 2005 |g 17(2021), 7 vom: 17. März, Seite 759-761 |w (DE-627)NLM161450725 |x 1744-8301 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2021 |g number:7 |g day:17 |g month:03 |g pages:759-761 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/fon-2020-0997 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2021 |e 7 |b 17 |c 03 |h 759-761 | ||